Occupational Activity – Page 21

Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes

11 months ago talkbio0Tagged Administration occupational activities, agonists, Diabetes, gastrointestinal tolerability, GLP-1 receptor, Obesity, therapeutic strategies

GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment

Sanofi Workers Strike Over Consumer Health Unit Sale Amid Job Loss and Strategic Asset Concerns

11 months ago talkbio0Tagged Clayton, consumer health unit, DOLIPRANE, France, losses, Opella, Sales - occupational activity, sanofi, strategic assets

Sanofi, strike, consumer health unit, sale, job losses, strategic assets, France, Doliprane, Opella, Clayton Dubilier & Rice

MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial

11 months ago talkbio0Tagged AAV-GAD, Clinical Trials, dopamine, gamma-aminobutyric acid, gene therapy, MeiraGTx, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Phase 2 trial, production, Quality of life, Surgical Replantation

MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production

WuXi AppTec and WuXi Biologics Consider Asset Sales Amid BIOSECURE Act Scrutiny

11 months ago talkbio0Tagged AppTec, asset, Biological Factors, BIOSECURE, Industry, Relations, Sales - occupational activity, U.S.-China, WuXi

WuXi AppTec, WuXi Biologics, BIOSECURE Act, asset sales, biotech industry, US-China relations

Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes

11 months ago talkbio0Tagged Arenaria, Biological Factors, Changing, Industry, Leadership, restructuring, strategic

Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry

Glooko Secures $100 Million Funding to Enhance Diabetes Management Platform Under New Leadership

11 months ago talkbio0Tagged Administration occupational activities, Diabetes, Glooko, Healthcare technology, Leadership

Glooko, diabetes management, healthcare technology, funding, new leadership

Judo Bio Launches with $100M to Pioneer Kidney-Targeted siRNA Therapies

11 months ago talkbio0Tagged genetic medicines, Judo Bio, Kidney Diseases, megalin-STRIKERS, oligonucleotide medicines, RNA, Small Interfering, Strikes, Employee

Judo Bio, siRNA therapies, kidney diseases, oligonucleotide medicines, STRIKE platform, megalin-STRIKERS, renal diseases, genetic medicines.

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

11 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Relay Therapeutics Announces Additional Layoffs to Achieve $50M Annual Savings

11 months ago talkbio0Tagged cost-cutting, Industry, Relay Therapeutics

Relay Therapeutics, layoffs, cost-cutting, biotech industry, workforce reduction

BIOSECURE Act: Navigating Industry Implications and Future Directions

11 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience